Detalhe da pesquisa
1.
Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification.
Diabet Med
; 41(2): e15200, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37578188
2.
The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis.
Nephrol Dial Transplant
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38730538
3.
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.
Nephrol Dial Transplant
; 38(5): 1260-1270, 2023 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36301617
4.
Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review.
Health Qual Life Outcomes
; 18(1): 310, 2020 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32957990
5.
Projecting the Epidemiological and Economic Impact of Chronic Kidney Disease Using Patient-Level Microsimulation Modelling: Rationale and Methods of Inside CKD.
Adv Ther
; 40(1): 265-281, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307575
6.
Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study.
Clin Kidney J
; 15(4): 738-746, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35371463
7.
Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants.
Adv Ther
; 38(2): 1352-1363, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33474707